Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL

British Journal of Haematology

Volumn 157, Issue 5, 2012, Pages 543-552

  Moore, Sally ^a   Kayani, Irfan ^a   Peggs, Karl ^a   Qian, Wendi ^b   Lowry, Lisa ^a   Thomson, Kirsty ^a   Linch, David C ^a   Ardeshna, Kirit ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Brentuximab vedotin; Hodgkin lymphoma; Mini BEAM; Refractory lymphoma; Salvage chemotherapy

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; OFATUMUMAB; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; PATIENT; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; VERY POOR RISK PATIENT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MELPHALAN; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860834338     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09096.x     Document Type: Article

References (35)

1. Anderlini, P., Saliba, R., Acholonu, S., Okoroji, G.J., Donato, M., Giralt, S., Andersson, B., Ueno, N.T., Khouri, I., De Lima, M., Hosing, C., Ippolito, C., Romaguera, J., Rodriguez, M.A., Pro, B., Fayad, L., Goy, A., Younes, A. & Champlin, R.E. (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplantation, 35, 943-951.
2. Ardeshna, K.M., Kakouros, N., Qian, W., Powell, M.G., Saini, N., D'Sa, S., Mackinnon, S., Hoskin, P.J., Goldstone, A.H. & Linch, D.C. (2005) Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. British Journal of Haematology, 130, 363-372.
3. Canales, M.A., Fernandez-Jimenez, M.C., Martin, M.C., Arrieta, R., Cabellero, M.D., Diez, J., Quevedo, E., Garcia-Bustos, J., San Miguel, J.F. & Hernandez-Navarro, F. (2001) Identification factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica, 86, 494-498.
4. Chen, R.W., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., Engert, A., Larsen, E.K., Kennedy, D.A., Sievers, E.L. & Younes, A. (2011) Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). Journal of Clinical Oncology, 29(Suppl 15), Abstract 8031.
5. Cheson, B., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
6. Chopra, R., Linch, D.C., McMillan, A.K., Blair, S., Patterson, K.G., Moir, D., Richards, J.D., Cervi, P., Kinsey, S. & Goldstone, A.H. (1992) Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. British Journal of Haematology, 81, 197-202.
7. Colwill, R., Crump, M., Couture, F., Danish, R., Stewart, A.K., Sutton, D.M., Scott, J.G., Sutcliffe, S.B., Brandwein, J.M. & Keating, A. (1995) Mini-BEAM as salvage therapy for refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. Journal of Clinical Oncology, 13, 396-402.
8. Cunningham, D., Smith, P., Mouncey, P., Qian, W., Jack, S., Pocock, C., Ardeshna, K., Radford, J.A., Davies, A.J., McMillan, A. & Linch, D.C. (2011) R-CHOP14 versus R-CHOP 21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. Journal of Clinical Oncology (ASCO Meeting Abstracts), 29, 8000.
9. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dorken, B., Ludwig, W.D., Koch, P., Hanel, M., Pfreundschuh, M., Wilhelm, M., Trumper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Muller-Hermelink, H.K., Hasenclever, D. & Loffler, M. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma:10 years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology, 27, 4548-4554.
10. Freudenberg, L.S., Antoch, G., Schutt, P., Beyer, T., Jentzen, W., Muller, S.P., Gorges, R., Nowrousian, M.R., Bockisch, A. & Debatin, J.F. (2004) FDG-PET/CT in re-staging of patients with lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 31, 325-329.
11. Girouard, C., Dufresne, J., Imrie, K., Stewart, A.K., Brandwein, J., Prince, H.M., Pantolony, D., Keating, A. & Crump, M. (1997) Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Annals of Oncology, 8, 675-680.
12. Gribben, J.G., Goldstone, A.H., Linch, D.C., Taghipour, G., McMillan, A.K., Souhami, R.L., Earl, H. & Richards, J.D. (1989) Effectiveness of high-dose chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. Journal of Clinical Oncology, 7, 1621-1629.
13. Jabbour, E., Hosing, C., Ayers, G., Nunez, R., Anderlini, P., Pro, B., Younes, A., Hagemeister, F., Kwah, L. & Fayad, L. (2007) Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer, 109, 2481-2489.
14. Johnson, P.W., Sydes, M.R., Hancock, B.W., Cullen, M., Radford, J.A. & Stenning, S.P. (2010) Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma; survival data from the UKLG LY09 randomized control trial (ISRCTN97144519). Journal of Clinical Oncology, 28, 3352-3359.
15. Josting, A., Muller, H., Borchmann, P., Baars, J.W., Metzner, B., Dohner, H., Aurer, I., Smardova, L., Fischer, T., Niederwieser, D., Schafer-Eckhart, K., Schmitz, N., Sureda, A., Glossmann, J., Diehl, V., Dejong, D., Hansmann, M.L., Raemaekers, J. & Engert, A. (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. Journal of Clinical Oncology, 28, 5074-5080.
16. Kasamon, Y.L., Jones, R.J. & Wahl, R.L. (2007) Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. Journal of Nuclear Medicine, 48(Suppl. 1), 19S-27S.
17. Kuruvilla, J., Nagy, T., Pintilie, M., Tsang, R., Keating, A. & Crump, M. (2006) Similar response rates and earlier progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine etoposide, cytarabine and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer, 106, 353-360.
18. Lambert, J.R., Bomanji, J.B., Peggs, K.S., Thomson, K.J., Chakraverty, R.K., Fielding, A.K., Kottaridis, P.D., Roughton, M., Morris, E.C., Goldstone, A.H., Linch, D.C., Ell, P.J. & Mackinnon, S. (2010) Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood, 115, 2763-2768.
19. Linch, D.C., Gosedn, R.G., Tulandi, T., Tan, S.L. & Hancock, S.L. (2000) Hodgkin's lymphoma: choice of therapy and late complications. American Society of Haematology Educational Program, 2, 205-221.
20. Martin, A., Fernandez-Jimenez, M.C., Caballero, M.D., Canales, M.A., Perez-Simon, J.A., Garcia de Bustos, J., Vazquez, L., Hernandez-Navarro, F. & San Miguel, J.F. (2001) Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. British Journal of Haematology, 113, 161-171.
21. Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A. & Mackinnon, S. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 3865-3871.
22. Morschhauser, F., Brice, P., Ferme, C., Divine, M., Salles, G., Bouabdallah, R., Sebban, C., Voillat, L., Casanovas, O., Stamatoullas, A., Bouabdallah, K., Andre, M., Jais, J.P., Cazals-Hatem, C. & Gisselbrecht, C. (2008) Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. Journal of Clinical Oncology, 26, 5980-5987.
23. Moskowitz, C.H., Kewalramani, T., Nimer, S.D., Gonzalez, M., Zelenetz, A.D. & Yahalom. (2004) Effectiveness of high dose chemotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. British Journal of Haematology, 124, 645-652.
24. Moskowitz, A., Yahalom, J., Kewalramani, T., Maragulia, J.C., Vanak, J.M., Zelenetz, A.D. & Moskowitz, C.H. (2010) Pretransplanation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood, 116, 4934-4937.
25. Oki, Y. & Younes, A. (2008) Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leukaemia and Lymphoma, 49, 883-889.
26. Peggs, K.S., Hunter, A., Chopra, R., Parker, A., Mahendra, P., Milligan, D., Craddock, C., Pettengell, R., Dogan, A., Thomson, K.J., Morris, E.C., Hale, G., Waldmann, H., Goldstone, A.H., Linch, D.C. & Mackinnon, S. (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. The Lancet, 365, 1934-1941.
27. Philip, T., Armitage, J.O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J.Y., Colombat, P., Goldstone, A.H., Gorin, N.C., Flesh, M., Laporte, P., Maraninchi, D., Pico, J., Bosly, A., Andersen, C., Schots, R., Biron, P., Cabanillas, F. & Dicke, K. (1987) High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New England Journal of Medicine, 316, 1493-1498.
28. Seyfarth, B., Josting, A., Dreyling, M. & Schmitz, N. (2006) Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. British Journal of Haematology, 133, 3-18.
29. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Balzarini, J., Wolf-Peeters, C.D., Mortelmans, L. & Verhoef, G. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, 53-59.
30. Stenger, M. (2011) FDA approves brentuximab vedotin in two lymphoma indications. ASCO Post, 2.
31. Sureda, A., Robinson, S., Canals, C., Carella, A.M., Boogaerts, M.A., Cabellero, D., Hunter, A.E., Kanz, L., Slavin, S., Cornelissen, J.J., Gramatzki, M., Niederwieser, D., Russell, N.H. & Schmitz, N. (2008) Reduced-intensity conditioning compared to conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma; an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 26, 455-462.
32. Svoboda, J., Andreadis, C., Elstrom, R., Chong, E.A., Downs, L.H., Berkowitz, A., Luger, S.M., Porter, D.L., Nasta, S., Tsai, D., Loren, A.W., Siegel, D.L., Glatstein, E., Alavi, A., Stadtmauer, E.A. & Schuster, S.J. (2006) Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 38, 211-216.
33. Thomson, K.J., Morris, E.C., Bloor, A., Cook, G., Milligan, D., Parker, A., Clark, F., Yung, L., Linch, D.C., Chakraverty, R., Peggs, K.S. & Mackinnon, S. (2009) Favourable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 426-432.
34. Thomson, K., Kayani, I., Ardeshna, K.M., Morris, E., Hough, R., Goldstone, A.H., Linch, D.C. & Peggs, K.S. (2011) Response-adjusted transplantation in primary resistant and relapsed Hodgkin lymphoma. Blood (ASH annual meeting abstracts), 118, 336.
35. Watts, M.J., Sullivan, A.M., Jamieson, E., Pearce, R., Fielding, A., Devereux, S., Goldstone, A.H. & Linch, D.C. (1997) Progenitor-cell mobilization after low dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. Journal of Clinical Oncology, 15, 535-546.